

REPORT SUMMARY

THE SOCIO-ECONOMIC VALUE OF ADULT IMMUNISATION PROGRAMMES

Introduction

The world is currently undergoing significant demographic shifts with aging populations. Concurrently, infectious diseases, along with rising rates of chronic diseases amongst younger populations, are placing immense pressure on healthcare systems.

Addressing these challenges requires a paradigm shift from treatment to prevention.

- Vaccination is a fundamental preventive measure, integral to achieving global health and development goals like the UN Sustainable Development Goals (SDGs) and the Immunization Agenda 2030.

The value of adult immunisation programmes often remains overlooked.

- Access to adult vaccinations is inconsistent across countries, with limited inclusion in routine immunisation schedules.

Key Takeaways



Adopt a prevention-first mindset. Implement and optimise robust adult immunisation programmes.



Expand and develop the evidence base for the value of adult immunisation programmes.



Adult immunisation programmes help our societies age well and sustainably long into the future while delivering an excellent return on investment.

Adult immunisation programmes can offset their costs multiple times

19x

Adult vaccines can return **up to 19 times their initial investment to society**, when their significant benefits beyond the healthcare system are monetised.

This 19x return is equivalent to billions of dollars in net benefits to society. Or, more concretely, **up to \$4637 per individual full vaccination course.**

up to \$4637
per full vaccination course

Background

The "triple-demic" of COVID-19, influenza, and RSV, along with rising rates of chronic diseases among younger age groups, places pressure on healthcare systems already grappling with treatment backlogs, challenges of antimicrobial resistance and other threats. Vaccination is a fundamental preventive measure for achieving global health goals like the SDGs.

The Value of Adult Immunisation

For Population Health

Vaccine-preventable diseases continue to impose a substantial burden on adult populations, causing mortality and severe health consequences.

For Healthcare Systems


Adult immunisation programmes are highly cost-effective and can result in net cost savings for healthcare systems.

For Society

Expanding adult immunisation programmes and coverage can lead to substantial productivity gains and economic benefits for society.

Percentage 100% 70-90% 40-60% 10-30% No evidence

	Impact on quality of life of vaccinated	Impact on mortality of vaccinated	Impact on quality of life of carers	Transmission value	Cost offsets to healthcare system	Value to other interventions	Impact on productivity of vaccinated	Impact on carer productivity	Social equity value	AMR prevention value	Macroeconomic effects
Influenza	100%	100%	No evidence	40-60%	70-90%	No evidence	40-60%	40-60%	No evidence	40-60%	No evidence
Pneumococcal	40-60%	40-60%	No evidence	40-60%	40-60%	No evidence	40-60%	40-60%	40-60%	No evidence	No evidence
RSV	40-60%	40-60%	No evidence	40-60%	40-60%	No evidence	No evidence	No evidence	No evidence	No evidence	No evidence
Herpes Zoster	70-90%	40-60%	No evidence	No evidence	40-60%	No evidence	40-60%	40-60%	No evidence	No evidence	No evidence



Which countries did we include?

Ten countries were selected to represent a range of healthcare systems, demographics, and vaccine schedules (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, and the United States).

Recommendations

Significant gaps in evidence indicate a critical need for further research to prioritise and enhance adult immunisation programmes for the benefit of health care systems, economies and society.

We call on policy- and decision-makers to:

- adopt a prevention-first mindset;
- implement and optimise robust adult immunisation programmes that are proven cost-effective;
- expand the evidence base for the broader value of adult immunisation.

Authors

Hania El Banhawi, Sulayman Chowdhury, Priscila Radu, Margherita Neri, Sian Besley, Eleanor Bell, Simon Brassel, Lotte Steuten

For further information please contact:

Lotte Steuten

Deputy Chief Executive, OHE

email: lsteuten@ohe.org

FIND OUT MORE



THIS REPORT WAS COMMISSIONED AND FUNDED BY THE INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS AND ASSOCIATIONS (IFPMA).